Printer Friendly

Affymetrix Releases Its Most Comprehensive Single Array for Genetic Studies.

SNP Array 5.0 Makes High-Volume, Whole-Genome Association Studies More Affordable and Provides Researchers With High-Quality Data Faster Than Before

SANTA CLARA, Calif. -- Affymetrix Inc. (NASDAQ:AFFX) today announced the full commercial launch of its SNP Array 5.0, the company's most comprehensive single array for genetic studies. Researchers are currently using the SNP Array 5.0 to better identify and understand complex diseases such as autism, autoimmunity, bipolar disease, cancer, diabetes and heart disease.

The Affymetrix SNP Array 5.0 features 500,000 single nucleotide polymorphisms (SNPs) from the original two-chip 500K Array Set, as well as more than 420,000 additional probes designed to measure other genetic differences, such as copy number variation. Compared to the 500K Array Set, the SNP Array 5.0 offers customers more than twice the genetic information per array and improves array processing time by more than 25 percent, all for the same price.

Nine high-volume customers have been using the SNP Array 5.0 as part of the product's limited commercial release. Scientists from the Autism Consortium, the Broad Institute and the Institute of Genetic Medicine at Johns Hopkins University have been using the SNP Array 5.0 to perform the most comprehensive genetic study on autism, which involves more than 5,000 samples.

"The new SNP Array 5.0 is quickly providing data of superior quality for half the previous effort," said Aravinda Chakravarti, Ph.D., Henry J. Knott Professor and director of the Institute of Genetic Medicine at Johns Hopkins University. "The affordable price has translated into our examining a larger number of samples. The autism study, in particular, is one of the first beneficiaries of this new technology."

The Affymetrix SNP Array 5.0 was developed in collaboration with the Broad Institute of Harvard and the Massachusetts Institute of Technology. "We believe that the future of whole-genome scanning must simultaneously query both SNP and copy number information in a single experiment," said Stacey Gabriel, Ph.D., director, National Center for Genotyping and Analysis at the Broad. "We are working towards both array-based laboratory methods and algorithmic improvements to make this possible."

"Although we observed highly concordant data between the Affymetrix SNP Array 5.0 and the 500K Array Set, we found the new SNP Array 5.0 to consistently achieve a higher call rate and require less than half the hands-on time for processing," said Shawn Levy, Ph.D., director of the Vanderbilt Microarray Shared Resource and Assistant Professor of Biomedical Informatics at Vanderbilt University Medical Center. "Not only is there time savings in the single hybridization compared to two hybridizations, but the overall protocol is more streamlined and efficient."

"For the past 15 years, Affymetrix has been committed to providing our customers with the required tools for the genetic studies that they wish to perform," said Sean George, Ph.D., vice president of the Academic Business Unit at Affymetrix. "We are constantly refining and enhancing our product portfolio to enable the power of genetic studies to be realized in larger and larger sample cohorts by delivering more genetic content at more affordable prices. The SNP Array 5.0 is a great example of this continued innovation."

The SNP Array 5.0 is the most recent addition to Affymetrix' line of genotyping products, including the 10K, 100K and 500K Arrays, which are all based on the proven Whole-Genome Sampling Assay. This technology is being used by more than 200 laboratories and has generated data for more than 150 peer-reviewed scientific publications.

Affymetrix continues to work with scientists from the Broad Institute on the design of the higher-density SNP Array 6.0, which is scheduled to launch later this year. This product is expected to measure more than 1 million SNP and copy number variations across the genome.

For more information on recent discoveries using Affymetrix genotyping products, please visit:

Researchers Uncover Key Pathways Behind ALS:

Researchers Discover Gene Contributing to Human Memory Performance:

Researchers Discover Genetic Variant Associated with Obesity in Humans:

Researchers Discover a New Susceptibility Gene for Juvenile Diabetes:

Dr. Aravinda Chakravarti is a paid member of the Scientific Advisory Board of Affymetrix; this potential conflict-of-interest is managed by the rules of Johns Hopkins University.

About Affymetrix

Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip([R])technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and more than 8,500 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., Bedford, Mass., and Singapore. The company maintains important sales and marketing operations in Europe and Asia, and has about 1,100 employees worldwide. For more information about Affymetrix, please visit the company's website at

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the success of the SNP 5.0 Array discussed in this press release; risks of the company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses; uncertainties relating to technological approaches, manufacturing, product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K/A for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

NOTE: Affymetrix, the Affymetrix logo and GeneChip([R]) are registered trademarks owned or used by Affymetrix Inc.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 20, 2007
Previous Article:IPcelerate Announces Impact Selling Training Program.
Next Article:Mentor Graphics Participates in Panels at DVCon.

Related Articles
Chips ahoy: microchips covered with DNA emerge as powerful research tools.
Duke University and Affymetrix Initiate Five-Year Translational Research Collaboration.
Affymetrix Technology Selected for World's Most Comprehensive Genetic Study on Autism; Autism Consortium Will Use Single GeneChip(R) Human Mapping...
Affymetrix 500K Array Used to Identify Memory Gene.
First African American Genome Scan for Disease Genes Will Use Affymetrix 500K Arrays.
Affymetrix Signs Three-Year Translational Medicine Agreement With Vanderbilt-Ingram Cancer Center.
German National Genome Research Network to Analyze More Than 17,000 DNA Samples Using Affymetrix Technology.
Illumina Infinium BeadChips Selected by Germany's National Genome Research Network to Support One of the World's Largest Genetic Disease Studies to...
Affymetrix Sets New Standard in Genotyping With Genome-Wide Human SNP Array 6.0.
Another layer of complexity: short lengths of RNA could provide new form of genetic control.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters